Amarin Corp Plc (AMRN)

[bubbarayjr]

IMPORTANT Note from PR: Purchasing Inventory to support 2X++ GUIDANCE

Inventory Purchases: Because the rate of Vascepa revenue growth is difficult to predict, including potentially significantly varied timing regarding FDA review of the sNDA, Amarin intends to purchase inventory during 2019 at a rate which could support at least twice the 2019 net total revenue guidance described above. Such purchases do not change Amarin’s revenue guidance. Rather, they prepare Amarin for a situation in which actual revenue turns out to be significantly higher than the guidance described above.